Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus POF in second-line gastric adenocarcinoma
NCT03788174Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate at 3 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03788174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788174.